NCT06027853 is a Phase 1 clinical trial of CLL1 CAR-NK cell injection in AML, Adult, sponsored by Zhejiang University.

Who is sponsoring NCT06027853?

NCT06027853 is sponsored by Zhejiang University.

What drugs are being tested in NCT06027853?

Interventions in NCT06027853: CLL1 CAR-NK cell injection.

What condition does NCT06027853 study?

NCT06027853 studies AML, Adult.

Is NCT06027853 still recruiting?

NCT06027853 is currently recruiting now. Last updated 7 September 2023.

Last reviewed 2023-09-07 · How we verify

NCT06027853

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia

Recruiting now Phase 1 Last updated 7 September 2023

What this trial tests

Phase 1 trial testing CLL1 CAR-NK cell injection in AML, Adult in 24 participants. Currently enrolling.

Timeline

10 September 2023

Primary endpoint
31 August 2026

31 August 2026

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	10 September 2023
Primary completion	31 August 2026
Estimated completion	31 August 2026
Sites	1 location across China

Drugs / interventions tested

CLL1 CAR-NK cell injection — full drug profile →

Conditions studied

AML, Adult — all drugs for AML, Adult →

Sponsor

Zhejiang University

Who can join

18 and older, any sex, with AML, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of CLL1 target CAR iPSC NK cells in patients with relapsed/refractory AML

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Development of NK cell-based cancer immunotherapies through receptor engineering.
Page A, Chuvin N, Valladeau-Guilemond J, Depil S. · · 2024 · cited 123× · PMID 38443448 · DOI 10.1038/s41423-024-01145-x
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization.
Chen S, Zhu H, Jounaidi Y. · · 2024 · cited 106× · PMID 39511139 · DOI 10.1038/s41392-024-02005-w
The clinical landscape of CAR NK cells.
Jørgensen LV, Christensen EB, Barnkob MB, Barington T. · · 2025 · cited 61× · PMID 40149002 · DOI 10.1186/s40164-025-00633-8
Unveiling the potential of CLL-1: a promising target for AML therapy.
Soleimani Samarkhazan H, Zehtabcheh S, Seraji HR, Beqaj SH, et al · · 2025 · cited 37× · PMID 39940055 · DOI 10.1186/s40364-025-00738-6
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.
Yao P, Liu YG, Huang G, Hao L, et al · · 2024 · cited 19× · PMID 39633491 · DOI 10.1186/s40164-024-00583-7
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.
Alidadi M, Barzgar H, Zaman M, Paevskaya OA, et al · · 2024 · cited 18× · PMID 39624236 · DOI 10.3389/fcell.2024.1491282
Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments.
Song SJ, Nam Y, Rim YA, Ju JH, et al · · 2024 · cited 18× · PMID 39574212 · DOI 10.1186/s13287-024-04065-9
Natural killer cell-based cancer immunotherapy: from basics to clinical trials.
Shi Y, Hao D, Qian H, Tao Z. · · 2024 · cited 17× · PMID 39415291 · DOI 10.1186/s40164-024-00561-z

Verify or expand the search:

Other recruiting trials for AML, Adult

Currently open trials in the same condition.

NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07132684 — Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients · Phase 3 · recruiting
NCT06533761 — Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML · Phase 1 · recruiting
NCT07117422 — Venetoclax-Decitabine in Untreated Elderly/Unfit AML · NA · recruiting
NCT06313437 — Revumenib in Combination With 7+3 + Midostaurin in AML · Phase 1 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06027853 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 7 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06027853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing